skip to main content

Recombinant human erythropoietin treatment improves platelet function in uremic patients

Cases, Aleix ; Escolar, Gines ; Reverter, Juan Carlos ; Ordinas, Antonio ; Lopez-Pedret, Jose ; Revert, Luis ; Castillo, Ricardo

Kidney International, September 1992, Vol.42(3), pp.668-672 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Recombinant human erythropoietin treatment improves platelet function in uremic patients
  • Autor: Cases, Aleix ; Escolar, Gines ; Reverter, Juan Carlos ; Ordinas, Antonio ; Lopez-Pedret, Jose ; Revert, Luis ; Castillo, Ricardo
  • Assuntos: Medicine
  • É parte de: Kidney International, September 1992, Vol.42(3), pp.668-672
  • Descrição: Recombinant human erythropoietin treatment improves platelet function in uremic patients. The effect of recombinant human erythropoietin (rHuEPO) on primary hemostasis was tested in 19 hemodialyzed patients. Bleeding time, platelet aggregation and platelet interaction with vessel subendothelium (SE) under flow conditions were determined before treatment and after patients reached hematocrits ≥30%. Two thrombotic events (an acute myocardial infarction and an AV fistula clotting) were recorded during the early stages of treatment. A shortening of average bleeding times (P 0.01), an increase in platelet count (P 0.01) and an improvement of platelet aggregation (P 0.01) and of platelet-SE interaction (P 0.01) were observed. A low correlation index was found between hematocrit and bleeding time (r = -0.351, P 0.05). To assess a possible effect of rHuEPO on platelet function, the same parameters were evaluated before and after receiving three doses of rHuEPO...
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.